Invitae Corporation

OTCPK:NVTA.Q Stock Report

Market Cap: US$114.6k

Invitae Valuation

Is NVTA.Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NVTA.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NVTA.Q's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NVTA.Q's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NVTA.Q?

Key metric: As NVTA.Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NVTA.Q. This is calculated by dividing NVTA.Q's market cap by their current revenue.
What is NVTA.Q's PS Ratio?
PS Ratio0.0002x
SalesUS$481.58m
Market CapUS$114.60k

Price to Sales Ratio vs Peers

How does NVTA.Q's PS Ratio compare to its peers?

The above table shows the PS ratio for NVTA.Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
FCHS First Choice Healthcare Solutions
4.6xn/aUS$108.8k
ETAO.F ETAO International
0.00003xn/aUS$1.5k
MEDV.F Medivolve
0.2xn/aUS$148.6k
CBDS Cannabis Sativa
6.9xn/aUS$5.1m
NVTA.Q Invitae
0.0002xn/aUS$114.6k

Price-To-Sales vs Peers: NVTA.Q is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does NVTA.Q's PS Ratio compare vs other companies in the US Healthcare Industry?

30 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.1.1x6.6%
NVTA.Q Invitae
 0.0002xn/aUS$114.60k
MCK McKesson
0.2x8.1%US$79.78b
CVS CVS Health
0.2x4.5%US$75.32b
NVTA.Q 0.0xIndustry Avg. 1.1xNo. of Companies30PS012345+
30 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.1x20.9%
NVTA.Q Invitae
 0.0002xn/aUS$114.60k
No more companies

Price-To-Sales vs Industry: NVTA.Q is good value based on its Price-To-Sales Ratio (0x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is NVTA.Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NVTA.Q PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.0002x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NVTA.Q's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$21.49

7D

5.0%

1Y

-19.4%

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

7D

-0.6%

1Y

-19.9%

Progyny

US$1.3b

A benefits management company, specializes in fertility and family building benefits solutions in the United States.

PGNY

US$15.57

7D

0.8%

1Y

-55.0%